Related Experiment Video
Updated: Jul 1, 2026
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
Abstract:
Pseudomyxoma peritonei is a rare condition consisting of mucinous ascites, most commonly arising from mucinous tumors of the appendix and occasionally from the ovary. Ronnett et al. have suggested a classification based on tumor pathology where they place all pseudomyxoma peritonei in three groups in order of decreasing prognosis: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinoma with intermediate or discordant features (PMCA) and peritoneal mucinous carcinoma (PMCA). Treatments are now standardized as a combination of cytoreductive surgery and perioperative intraperitoneal chemotherapy.
Insights
Pseudomyxoma peritonei, a rare condition of mucinous ascites, is classified into three pathological groups. Standardized treatment involves cytoreductive surgery and perioperative intraperitoneal chemotherapy.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- Pseudomyxoma peritonei is a rare clinical condition characterized by mucinous ascites.
- It most frequently originates from mucinous tumors of the appendix, but can also arise from ovarian tumors.
Observation:
- A classification system by Ronnett et al. categorizes pseudomyxoma peritonei into three distinct pathological groups.
- These groups, in order of decreasing prognosis, are disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinoma with intermediate or discordant features (PMCA), and peritoneal mucinous carcinoma (PMCA).
Findings:
- The classification provides a framework for understanding the pathological spectrum of pseudomyxoma peritonei.
- This pathological classification correlates with patient prognosis.
Implications:
- Standardized treatment protocols for pseudomyxoma peritonei now combine cytoreductive surgery with perioperative intraperitoneal chemotherapy.
- This approach aims to improve outcomes for patients diagnosed with this rare condition.
